SCHEMBL4095487

SCHEMBL4095487

COc1ccc2nc(-c3ccccc3F)nc(N3CCN(C(C)=O)CC3)c2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.63
LMNA P02545 1/20 0.63
HIF1A Q16665 1/20 0.50
GBA1 P04062 1/20 0.48
CFTR P13569 1/20 0.48
PDGFRB P09619 1/20 0.47
TSHR P16473 4/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
HSP90AA1 P07900 1/20 0.46
MTNR1B P49286 2/20 0.46
ABCG2 Q9UNQ0 1/20 0.45
USP2 O75604 3/20 0.45
CYP2D6 P10635 2/20 0.45
MAPK1 P28482 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
SIRT1 Q96EB6 1/20 0.44
NTSR1 P30989 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4097266 0.89 MAPT (0.59) MAPTLMNAHIF1ACFTRPDGFRB
SCHEMBL1083927 0.87 MAPT (0.68) MAPTLMNAHIF1ATSHRCYP1A2
SCHEMBL4095191 0.86 MAPT (0.62) MAPTLMNAHIF1AGBA1ABCG2
SCHEMBL4090816 0.85 HIF1A (0.68) MAPTLMNAHIF1AGBA1TSHR
SCHEMBL4753639 0.83 MAPT (0.61) MAPTLMNAHIF1AGBA1TSHR
SCHEMBL1084633 0.79 MEN1 (0.56) MAPTHIF1AGBA1PDGFRBTSHR
SCHEMBL4093185 0.78 MEN1 (0.51) GBA1PDGFRBTSHRCYP1A2CYP3A4
SCHEMBL23948078 0.78 MAPT (0.60) MAPTLMNAHIF1AGBA1TSHR
SCHEMBL29763687 0.78 MAPT (0.60) MAPTLMNAHIF1AGBA1TSHR
SCHEMBL4099593 0.78 HIF1A (0.51) MAPTLMNAHIF1AGBA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MAPT 4125/4885LMNA 2728/4885HIF1A 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.